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ABSTRACT
Diagnosis of eosinophilic esophagitis (EoE) and determination of response to therapy is based on histological assessment of
the esophagus, which requires upper endoscopy. In children, in whom a dietary approach is commonly used, multiple
endoscopies are needed, because foods are eliminated and then gradually reintroduced. Ideally, noninvasive methods could
supplement or replace upper endoscopy to facilitate management. Fractionated exhaled nitric oxide (FeNO) has been proposed
as a useful measure for monitoring disease activity in studies of patients with eosinophil-predominant asthma and in other
atopic disorders. Thus, we evaluated whether FeNO levels could be a useful biomarker to assess the response to therapy in EoE
patients. This study was designed to determine whether there is a change in FeNO levels during treatment with topical
corticosteroids and whether changes correlated with clinical response. This was a prospective, multicenter study that enrolled
nonasthmatic patients with established EoE. FeNO levels and symptom scores were measured at baseline, biweekly during
6-week swallowed fluticasone treatment, and 4 weeks posttreatment. Twelve patients completed the trial. We found a
statistically significant difference between median pre- and posttreatment FeNO levels [20.3 ppb (16.0–29.0 ppb) vs 17.6 ppb
(11.7–27.3 ppb), p0.009]. However, neither the pretreatment FeNO level, a change of FeNO level after 2 weeks of treatment, nor
the FeNO level at the end of treatment confidently predicted a clinical or histological response. Although our findings suggest nitric
oxide possibly has a physiological role in EoE, our observations do not support a role of FeNo determination for management of EoE.
(Allergy Asthma Proc 33:519–524, 2012; doi: 10.2500/aap.2012.33.3606)
E
osinophilic esophagitis (EoE) is a chronic, immune/
antigen-mediated esophageal disease characterized
clinically by symptoms related to esophageal dysfunction
and histologically by eosinophil-predominant inflamma-
tion.
1 The primary treatment options are topical cortico-
steroids and elimination of implicated foods. Diagnosis of
EoE and assessment of the response to therapy is based
on histological assessment of the esophagus, which re-
quires upper endoscopy. In children, in whom a dietary
approach is commonly used, multiple endoscopies are
often needed, because foods are eliminated and then
gradually reintroduced. Ideally, noninvasive methods
could supplement or replace upper endoscopy to facili-
tate management.
Fractionated exhaled nitric oxide (FeNO) has proven
to be a useful measure of disease activity in studies of
patients with eosinophil-predominant asthma.
2 FeNO
levels are also increased in other atopic diseases in
which eosinophils are thought to have an important
role.
3,4 Thus, we sought to evaluate whether FeNO
levels could be a useful biomarker to assess the re-
sponse to therapy in patients with EoE.
PATIENTS AND METHODS
Study Design and Study Participants
This was a prospective, multicenter pilot study that
enrolled nonasthmatic patients with established EoE.
Patients aged 7–65 years were recruited from the Tufts
Medical Center, Floating Hospital for Children, Bos-
ton, MA, and the Brigham and Women’s Hospital,
Boston, MA. All patients and all parents of adolescent
patients provided written informed consent. The study
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Patients with a clinical history consistent with EoE
and esophageal biopsy specimens showing a baseline
peak count of esophageal intraepithelial eosinophils
(peak eosinophil [PE]) 15 in at least 1 high-power
field (hpf) evaluated at 400 magnification, despite
6–8 weeks of twice-daily dosing of proton pump in-
hibitor (PPI) therapy were considered eligible. The def-
inition of EoE was consistent with consensus guide-
lines.
1
Patients were excluded if they had used inhaled,
nasal, or systemic corticosteroids within the past 3
months; had history of smoking; had undergone di-
etary modification for EoE in the last 6 months; had
history of doctor-diagnosed asthma or rhinitis; had a
major systemic illnesses (including cirrhosis, renal in-
sufficiency, heart failure, and respiratory disease); or
who were pregnant.
All patients were treated with swallowed fluticasone
at 440 g twice daily for 6 weeks. Techniques of swal-
lowing topical corticosteroids were reviewed at initia-
tion of therapy and reinforced during each visit (at
2-week intervals). Weekly phone calls were made dur-
ing the 10-week trial to advocate medial compliance.
All patients remained on twice-daily PPI therapy
throughout the study period.
FeNO levels were measured using Niox Mino (Aero-
crine AB, Solna, Sweden) in accordance with American
Thoracic Society guidelines.
5 Triplicates at 5-minute
intervals were obtained for each measurement pre-
treatment, biweekly during 6-week treatment period,
and 4-week posttreatment. Reference ranges for FeNO
levels in healthy controls overlap with those observed
in patients with asthma.
6 Nevertheless, in adults with
asthma, values 25 ppb (20 ppb in children) are asso-
ciated with decreased responsiveness to corticosteroids
compared with those with values 50 ppb (35 ppb in
children).
5 Similarly, a reduction of at least 20% in
FeNO from baseline values over 50 ppb (or 10 ppb
drop for baseline value 50 ppb) correlates with a
significant response to anti-inflammatory therapy.
5 Be-
cause cutoff values in eosinophilic gastrointestinal dis-
orders have not been evaluated, we did not prespecify
threshold ranges but rather examined the changes in
FeNO levels during and after therapy.
Patients were instructed to complete a question-
naire to determine symptom score during each time
point. We used a scoring system that has previously
been studied in patients with EoE,
7 albeit no symp-
tom scoring questionnaire has been fully validated in
patients with EoE. Advantages of this scoring system
compared with other symptom scores used in esoph-
ageal disease are its explicit inclusion of clinical
features known to be associated with EoE including
dysphagia, chest pain, heartburn, regurgitation, vomit-
ing, and abdominal pain. Each symptom was scored
from 0 to 3 (0, absent; 1, three or less times per week; 2,
three to six times per week; and 3, daily), with a total
possible score of 18.
Patients who continued to be symptomatic after
treatment were offered a repeat upper endoscopy. At
least four biopsy specimens were taken from the prox-
imal half and lower half of the esophagus. All biopsy
specimens were reviewed by a single board-certified
pathologist. Patients were considered to be histological
responders if the PE count was 7/hpf.
8
Statistical Methods and Data Analysis
All analyses were made using GraphPad Prism
Version 5.04 for Windows (GraphPad Software, La
Jolla, CA). FeNO level, PE count and symptom
scores were represented as median and interquartile
range. Using each patient as his/her own control, we
compared the FeNO level, PE count, and symptom
score at different time points using Wilcoxon
matched-paired signed-rank tests. For the post hoc
analysis, we compared FeNO level, PE count, and
symptom score at different time points between
treatment responders and nonresponders using
Mann-Whitney test. The association between PE
count, FeNO, and symptom scores was analyzed
using Spearman rank correlation coefficient. A
Spearman rank correlation coefficient of 0.5–1 was
considered a strong correlation, 0.3–0.5 a weak cor-
relation, and 0.3 no correlation. A value of p  0.05
was considered significant.
RESULTS
Participant Flow and Demographics
Between September 2010 and September 2011, 29
nonasthmatic patients with a clinical history consistent
with EoE and esophageal biopsy specimens showing
PE count 15/hpf were screened for study participa-
tion (Fig 1). Fourteen met the eligibility criteria and
were enrolled. The reasons for ineligibility were use of
corticosteroids in the past three months (n  2), history
of asthma (n  6), esophageal eosinophilic infiltration
that resolved with high dose PPI (n  4), and patient
refusal (n  3).
Two patients dropped out of the study, both within
3 weeks of enrollment. One dropped out because of job
relocation to another state and the other because of
work schedule conflict. The 12 remaining patients com-
pleted the study. One patient developed esophageal
candidiasis during the study period and was excluded
from our data analysis.
Ten of the 11 patients were adults. Demographics
and baseline characteristics are summarized in Table 1.
The majority of the patients were male (8/11), treat-
ment naïve (9/11), had esophageal rings (8/11), and
520 November–December 2012, Vol. 33, No. 6had a history of food impaction (8/11). Overall com-
pliance to medical therapy was reported to be above
95% (a total of 46 missed doses out of a total of 924
expected doses).
Reduction of FeNO Levels and Symptom Score
with Treatment
There was a statistically significant difference be-
tween the median pre- and posttreatment FeNO level
(20.3 ppb [16.0–29.0 ppb] versus 17.6 ppb [11.7–27.3
ppb]; p  0.009; Fig. 2). Two weeks posttreatment,
FeNO returned to 23.4 ppb (17.3–34.1 ppb), which was
not significantly different from pretreatment level (p 
0.55).
Similarly, there was a statistically significant reduc-
tion in the median symptom score pre- and posttreat-
ment (3.0 [3.0–6.0] versus 1.0 [0.0–3.0]; p  0.006).
Although the median symptom score increased 2
weeks after discontinuation of treatment from 1.0 (0.0–
3.0) to 2.5 (0.0–3.5), the change did not reach statistical
significance (p  0.44).
Histological Response to Treatment
All 12 patients who completed 6 weeks of treatment
reported continued symptoms and elected to undergo
a repeat upper endoscopy. One had severe esophageal
candidiasis and was excluded from the analysis.
Among the remaining 11, only 5 (45%) responded his-
tologically (PE count 7/hpf as defined previously).
The pretreatment PE was 23.0 (18.5–36.0) in respond-
ers, versus 68 (35.8–102.5) in nonresponders (p 
0.017). There was no significant difference between the
baseline symptom scores or FeNO levels between re-
sponders and nonresponders (p  1.0 and 0.33, respec-
tively; Table 2).
FeNO Levels in Responders and Nonresponders
The median reduction of FeNO levels after treat-
ment was more apparent in histological responders
(26.7%), than in nonresponders (18.7%), although
the difference did not reach statistical significance
(p  0.08). We explored whether a reduction of FeNO
in the first 2 weeks could predict response to treat-
ment. It was similar in both groups (27.9% in re-
sponders versus 26.5% in nonresponders; p  0.24),
suggesting initial reduction of FeNO because treat-
ment can not predict treatment response.
There was no significant correlation between
FeNO and symptom scores when the data were an-
Figure 1. Participant flow.
Table 1 Baseline demographics and clinical
characteristics
Age, yr (SD) 34 (13)
Sex, n (%)
Female 3 (27)
Male 8 (73)
Race, n (%)
White 11 (100)
Black 0 (0)
Asian 0 (0)
Body mass index, mean
(SD) (kg/m
2)
26 (4.2)
Smoking, n (%) 0 (0)
Duration of EoE, mean
(SD) (mo)
12 (20)
Age at onset of EoE, yr 33.2 (12.6)
Treatment naïve, n (%) 9 (82)
Concomitant PPI use, n (%) 11 (100)
Peripheral eosinophil
count, mean (SD)
(1000/mm
3)
0.48 (0.27)
Peak esophageal eosinophil
count, median (IQR)
(cells/hpf)
36 (23–76)
Symptom score, median
(IQR)
3.0 (3.0–6.0)
FeNO level, median (IQR)
(ppb)
20.3 (16.0–29.0)
History of food impaction,
n (%)
8 (73)
Frequency of symptoms,
n (%)
Dysphagia 11 (100)
Chest pain 2 (18)
Heartburn 7 (64)
Regurgitation 3 (27)
Vomiting 3 (27)
Abdominal pain 4 (36.4)
EoE  eosinophilic esophagitis; PPI  proton pump inhib-
itor; IQR  interquartile range.
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analysis, we found a modest but significant associa-
tion between symptom scores and FeNO levels in
histological responders (r  0.51; p  0.005; Fig. 3).
There was no association between symptom scores
and PE count, or FeNO levels with PE count in either
group.
DISCUSSION
We found a modest but statistically significant re-
duction of FeNO level with treatment and a modest
correlation between FeNO level and symptom scores
among histological responders. In post hoc analysis, we
found that neither the pretreatment FeNO level nor the
change in FeNO level after 2 weeks of treatment pre-
dicted treatment response.
In the post hoc analysis, we found that the median
PE count dropped from 36 (23–76) to 20 (5–60) in all
treated patients (p  0.029). This observation sug-
gests that reduction in FeNO levels (20.3 ppb [16.0–
29.0 ppb] pretreatment versus 17.6 ppb [11.7–27.3
ppb] posttreatment; p  0.009) might reflect a reduc-
tion in eosinophil burden with treatment. Neither
systemic
9 nor nasal instilled
10 corticosteroids di-
rectly affect FeNO levels in healthy individuals.
Thus, the reduction of FeNO level was unlikely to
Figure 2. Box and Whisker plot of FeNO levels (upper panels) and symptom scores (lower panels) of all patients, responders and
non-responders.
Table 2 Baseline characteristics of treatment responders and nonresponders
Responders Nonresponders p Value
Peak esophageal eosinophil count,
median (IQR) (cells/hpf)
23.0 (18.5–36.0) 68.0 (35.8–102.5) 0.05
Symptom score, median (IQR) 3.0 (2.5–8.0) 3.5 (2.8–6.0) 1.0
FeNO level, median (IQR) (ppb)
Week 0 24.0 (16.2–63.4) 19.5 (13.4–24.5) 0.33
Week 2 17.3 (13.4–40.2) 14.3 (11.0–21.6) 0.20
IQR  interquartile range.
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tion. None of the patients enrolled were tobacco
smokers or had clinician-diagnosed asthma or rhini-
tis, which have been associated with elevated
FeNO.
5,11 Although we did not include spirometry
and/or bronchoprovocation testing as part of the
objective evaluation to exclude patients with asthma,
the absence of asthma symptoms, history of doctor-
diagnosed asthma, or need for inhaled corticoste-
roids make clinically important asthma unlikely.
Nevertheless, it is possible that some of our patients
had undetected atopic conditions that may have con-
tributed to the FeNO levels.
Most of the research on FeNO has focused on upper
and lower airway diseases. In 1991, Gustafsson and
coworkers
12 discovered that NO is present in exhaled
breath of humans, and 2 years later Alving and col-
leagues
13 showed that FeNO is increased in patients
with asthma. These findings triggered a great interest
in studying various aspects of FeNO and 1000 arti-
cles have been subsequently published. In 2005, Smith
et al.
14 showed in a randomized, single-blinded and
placebo-controlled trial that use of FeNO measure-
ments significantly reduced the maintenance doses of
inhaled corticosteroids without compromising asthma
control, although this finding has recently been chal-
lenged
15 and the role of FeNO in guiding asthma man-
agement remains to be defined.
16–18
More recent studies found elevated FeNO levels in
patients who were atopic but did not have asthma
6,19and
in nonatopic, nonasthmatic patients with Hodgkin’s lym-
phoma.
20 Atopic dermatitis has also been associated with
elevated FeNO levels.
11 These observations suggested a
possible role for FeNO in immunologic diseases not re-
stricted to the airways.
The role of NO has been intensively studied in in-
flammatory bowel disease (IBD). Human and animal
studies convincingly showed that NO production is
up-regulated in IBD and correlates with disease activ-
ity.
21–30 In 2002, Koek et al. reported that FeNO levels
were elevated in IBD patients and correlated with dis-
ease activity,
28 suggesting that gastrointestinal inflam-
mation could elevate FeNO levels. None of our pa-
tients had IBD.
In summary, our study found a modest reduction of
FeNO level with EoE treatment and a modest signifi-
cant correlation between FeNO level and symptom
scores among histological responders. However, we
did not find that pretreatment FeNO level or change in
FeNO levels were helpful in predicting treatment re-
sponse. Thus, while our findings suggest NO possibly
has a physiological role in EoE, our observations do not
support a role for FeNO determination in the manage-
ment of EoE.
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